209 related articles for article (PubMed ID: 9778086)
1. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.
Kleiman NS; Lincoff AM; Ohman EM; Harrington RA
Am Heart J; 1998 Oct; 136(4 Pt 2 Su):S32-42. PubMed ID: 9778086
[TBL] [Abstract][Full Text] [Related]
2. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
3. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
[TBL] [Abstract][Full Text] [Related]
4. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
6. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond.
Manoharan G; Adgey AA
Heart; 2001 Sep; 86(3):259-61. PubMed ID: 11514474
[No Abstract] [Full Text] [Related]
8. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
9. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention].
Kakuta T; Kishi Y; Numano F
Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330
[TBL] [Abstract][Full Text] [Related]
10. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
11. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
12. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
Roffi M; Chew DP; Mukherjee D; Bhatt DL; White JA; Moliterno DJ; Heeschen C; Hamm CW; Robbins MA; Kleiman NS; Théroux P; White HD; Topol EJ
Eur Heart J; 2002 Sep; 23(18):1441-8. PubMed ID: 12208224
[TBL] [Abstract][Full Text] [Related]
14. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials.
Cannon CP
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-14-7. PubMed ID: 11129681
[TBL] [Abstract][Full Text] [Related]
15. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
Circulation; 1998 Jun; 97(24):2386-95. PubMed ID: 9641689
[TBL] [Abstract][Full Text] [Related]
16. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Harrington RA
Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
[TBL] [Abstract][Full Text] [Related]
17. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
Am Heart J; 1998 Apr; 135(4):S56-66. PubMed ID: 9539496
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes.
Elmouchi DA; Bates ER
Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523
[TBL] [Abstract][Full Text] [Related]
19. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Subbarao VD; Phillips J; Stouffer GA
Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.
Antman EM
Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
